Alice T Shaw

Alice T Shaw

UNVERIFIED PROFILE

Are you Alice T Shaw?   Register this Author

Register author
Alice T Shaw

Alice T Shaw

Publications by authors named "Alice T Shaw"

Are you Alice T Shaw?   Register this Author

100Publications

4738Reads

40Profile Views

Association between circulating tumor DNA burden and disease burden in patients with ALK-positive lung cancer.

Cancer 2020 Aug 5. Epub 2020 Aug 5.

Division of Thoracic Imaging and Intervention, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.33118DOI Listing
August 2020

Clinicopathologic Characteristics of BRG1-Deficient NSCLC.

J Thorac Oncol 2020 May 24;15(5):766-776. Epub 2020 Jan 24.

Center for Integrated Diagnostics, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2020.01.002DOI Listing
May 2020

Imaging Features and Metastatic Patterns of Advanced -Rearranged Non-Small Cell Lung Cancer.

AJR Am J Roentgenol 2020 04 30;214(4):766-774. Epub 2019 Dec 30.

Department of Radiology, Massachusetts General Hospital, 55 Fruit St, Founders 202, Boston, MA 02114.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.19.21982DOI Listing
April 2020

Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.

Clin Lung Cancer 2020 03 16;21(2):153-159.e3. Epub 2019 Oct 16.

Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.10.006DOI Listing
March 2020

Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with Rearrangements.

Cancers (Basel) 2020 Mar 15;12(3). Epub 2020 Mar 15.

Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12030693DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140075PMC
March 2020

Resistance looms for KRAS inhibitors.

Nat Med 2020 02;26(2):169-170

Novartis Institutes of Biomedical Research, Cambridge, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-020-0765-zDOI Listing
February 2020

Treatment with Next-Generation ALK Inhibitors Fuels Plasma Mutation Diversity.

Clin Cancer Res 2019 11 29;25(22):6662-6670. Epub 2019 Jul 29.

Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-1436DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858956PMC
November 2019

Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis.

Clin Lung Cancer 2019 09 11;20(5):339-349. Epub 2019 May 11.

Department of Radiology, Massachusetts General Hospital, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.05.006DOI Listing
September 2019

Clinical Management of Adverse Events Associated with Lorlatinib.

Oncologist 2019 08 19;24(8):1103-1110. Epub 2019 Mar 19.

Massachusetts General Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0380DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693708PMC
August 2019

Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History.

J Thorac Oncol 2019 05 18;14(5):835-843. Epub 2019 Jan 18.

Massachusetts General Hospital, Center for Integrated Diagnostics, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.032DOI Listing
May 2019

Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC.

J Thorac Oncol 2019 05 18;14(5):816-824. Epub 2019 Jan 18.

Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486857PMC
May 2019

BRAF Mutation Class and Clinical Outcomes-Response.

Clin Cancer Res 2019 05;25(10):3189

Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-0422DOI Listing
May 2019

Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases.

J Thorac Oncol 2019 04 7;14(4):683-690. Epub 2018 Dec 7.

Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183351
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.12.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440803PMC
April 2019

Refining precision cancer therapy in ALK-positive NSCLC.

EBioMedicine 2019 Mar 6;41:9-10. Epub 2019 Feb 6.

Massachusetts General Hospital Cancer Center, Boston, MA, USA; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2019.01.059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444055PMC
March 2019

Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional class.

Lung Cancer 2019 03 16;129:80-84. Epub 2019 Jan 16.

Department of Radiology, Massachusetts General Hospital, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002193002
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2019.01.007DOI Listing
March 2019

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.

Clin Cancer Res 2019 01 17;25(1):158-165. Epub 2018 Sep 17.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-2062DOI Listing
January 2019

Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.

J Thorac Oncol 2018 11;13(11):e226-e227

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183077
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.06.021DOI Listing
November 2018

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.

J Clin Oncol 2018 09 16;36(26):2693-2701. Epub 2018 May 16.

D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Dae Ho Lee, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Corey J. Langer, University of Pennsylvania, Philadelphia, PA; Alice T. Shaw, Massachusetts General Hospital, Boston; William Reichmann, Jeff Haney, Tim Clackson, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; Rudolf M. Huber, University Hospital of Munich, Munich, Germany; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Lyudmila A. Bazhenova and Kathryn A. Gold, University of California San Diego Moores Cancer Center, La Jolla; Sai-Hong Ignatius Ou, University of California Irvine School of Medicine, Irvine, CA; Howard L. West, Swedish Cancer Institute, Seattle, WA; and Scott N. Gettinger, Yale Cancer Center, New Haven, CT.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.77.5841
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.77.5841DOI Listing
September 2018

Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.

Lung Cancer 2018 08 22;122:67-71. Epub 2018 May 22.

Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.05.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062851PMC
August 2018

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.

Cancer Res Treat 2018 Jul 6;50(3):691-700. Epub 2017 Jul 6.

State Key Laboratory of South China, Hong Kong Cancer Institute and The Chinese University of Hong Kong, Shatin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2017.280DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056984PMC
July 2018

Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases.

Int J Radiat Oncol Biol Phys 2018 07 22;101(3):624-629. Epub 2018 Mar 22.

Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2018.02.175DOI Listing
July 2018

Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma.

Cancer Discov 2018 07 17;8(7):822-835. Epub 2018 May 17.

Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-0099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030433PMC
July 2018

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

J Clin Oncol 2018 04 26;36(12):1199-1206. Epub 2018 Jan 26.

Jessica J. Lin, Satoshi Yoda, Beow Y. Yeap, Ibiayi Dagogo-Jack, Nicholas A. Jessop, Ginger Y. Jiang, Long P. Le, Aaron N. Hata, Justin F. Gainor, Anthony J. Iafrate, and Alice T. Shaw, Massachusetts General Hospital, Boston; Alexa B. Schrock, Kyle Gowen, Philip J. Stephens, Jeffrey S. Ross, Siraj M. Ali, and Vincent A. Miller, Foundation Medicine, Cambridge, MA; Viola W. Zhu and Sai-Hong Ignatius Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; Melissa L. Johnson, Sarah Cannon Research Institute; and Christine M. Lovly, Vanderbilt-Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.2294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903999PMC
April 2018

Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.

J Thorac Oncol 2018 04 31;13(4):550-558. Epub 2018 Jan 31.

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183003
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.01.012DOI Listing
April 2018

Tumour heterogeneity and resistance to cancer therapies.

Nat Rev Clin Oncol 2018 02 8;15(2):81-94. Epub 2017 Nov 8.

Department of Medicine, Massachusetts General Hospital, 32 Fruit Street, Yawkey 7B, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.166DOI Listing
February 2018

ALK inhibitors in non-small cell lung cancer: how many are needed and how should they be sequenced?

Authors:
Alice T Shaw

Clin Adv Hematol Oncol 2017 Dec;15(12):941-945

Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
December 2017

Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas.

Am Soc Clin Oncol Educ Book 2017 ;37:619-629

From the Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hematology/Oncology Fellowship Program, Moffitt Cancer Center, Tampa, FL; University of South Florida, Tampa, FL; Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_175197DOI Listing
November 2017

Recent Advances in Targeting ROS1 in Lung Cancer.

J Thorac Oncol 2017 11 14;12(11):1611-1625. Epub 2017 Aug 14.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.08.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659942PMC
November 2017

Fast, Food and Ceritinib in ALK-Positive NSCLC.

J Thorac Oncol 2017 09;12(9):1341-1343

Department of Medicine, Massachusetts General Hospital, Boston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.07.012DOI Listing
September 2017

Expanding the Roster of ROS1 Inhibitors.

J Clin Oncol 2017 08 18;35(23):2595-2597. Epub 2017 May 18.

Ibiayi Dagogo-Jack and Alice T. Shaw, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.2586DOI Listing
August 2017

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

N Engl J Med 2017 08 6;377(9):829-838. Epub 2017 Jun 6.

From Lausanne University Hospital, Lausanne (S.P.), and F. Hoffmann-La Roche, Basel (A.Z., E.M., S. Golding, B.B., J.N.) - both in Switzerland; University of Colorado, Denver (D.R.C.); Massachusetts General Hospital, Boston (A.T.S.); University of Michigan, Ann Arbor (S. Gadgeel); Samsung Medical Center, Sungkyunkwan University School of Medicine (J.S.A.), and Seoul National University Hospital (D.-W.K.) - both in Seoul, South Korea; Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (S.-H.I.O.); Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France (M.P.); Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland (R.D.); Catalan Institute of Oncology, Barcelona (R.R.); Roche Innovation Center, New York (P.N.M.); and State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong (T.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1704795DOI Listing
August 2017

J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer.

Lancet 2017 07 10;390(10089):3-4. Epub 2017 May 10.

Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(17)31074-7DOI Listing
July 2017

ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.

J Thorac Oncol 2017 05 11;12(5):872-877. Epub 2017 Jan 11.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.01.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403618PMC
May 2017

Lung Cancer: A Wily Genetic Opponent.

Cell 2017 05;169(5):777-779

Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2017.05.001DOI Listing
May 2017

A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.

J Immunother 2017 04;40(3):108-113

*Massachusetts General Hospital Cancer Center †Department of Radiology, Massachusetts General Hospital, Harvard Medical School ‡Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000159DOI Listing
April 2017

Targeting ALK: Precision Medicine Takes on Drug Resistance.

Cancer Discov 2017 02 25;7(2):137-155. Epub 2017 Jan 25.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-1123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296241PMC
February 2017

Raising the bar on first-line immunotherapy in lung cancer.

Lancet Oncol 2017 01 5;18(1):2-3. Epub 2016 Dec 5.

Department of Thoracic Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30594-0DOI Listing
January 2017

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 12 31;34(34):4079-4085. Epub 2016 Oct 31.

Shirish M. Gadgeel, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Alice T. Shaw, Massachusetts General Hospital; Leena Gandhi, Dana-Farber Cancer Institute, Boston, MA; Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; D. Ross Camidge, University of Colorado Cancer Center, Denver, CO; Alberto Chiappori, Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Sai-Hong Ignatius Ou, University of California at Irvine, Orange, CA; Luigi De Petris, Karolinska Institutet, Stockholm, Sweden; Dong-Wan Kim, Seoul National University Hospital, Seoul; Ji-Youn Han, Lung Cancer Centre, National Cancer Centre, Goyang, South Korea; Denis L. Moro-Sibilot, Service de Pneumologie; Michael Duruisseaux, Centre Hospitalier Universitaire de Grenoble, Grenoble; Eric Dansin, Centre Oscar Lambret, Lille, France; Lucio Crino, Santa Maria della Misericordia Hospital, Perugia; Tommaso De Pas, European Institute of Oncology, Milan, Italy; Antje Tessmer, Evangelische Lungenklinik Berlin, Berlin, Germany; James Chih-Hsin Yang, Graduate Institute of Oncology and Cancer Research Centre, National Taiwan University, Taipei, Taiwan; and Walter Bordogna, Sophie Golding, and Ali Zeaiter, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.4639DOI Listing
December 2016

Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.

J Thorac Oncol 2016 11 17;11(11):2027-2032. Epub 2016 Aug 17.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.08.126DOI Listing
November 2016

Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies.

J Thorac Oncol 2016 11 20;11(11):2022-2026. Epub 2016 Aug 20.

Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864163084
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2016.06.032DOI Listing
November 2016

Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter?

J Clin Oncol 2016 10 25;34(28):3363-5. Epub 2016 Jul 25.

Massachusetts General Hospital Cancer Center, Boston, MA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.5891DOI Listing
October 2016

Challenge of Prognostic Uncertainty in the Modern Era of Cancer Therapeutics.

J Clin Oncol 2016 Oct;34(30):3605-3608

Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.8573DOI Listing
October 2016

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping.

J Thorac Oncol 2016 09 11;11(9):1522-8. Epub 2016 Jun 11.

Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.05.031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002360PMC
September 2016

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.

J Thorac Oncol 2016 08 22;11(8):1242-1245. Epub 2016 Jun 22.

Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.06.013DOI Listing
August 2016

Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.

Oncologist 2016 08 27;21(8):964-73. Epub 2016 Jun 27.

Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0508DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978553PMC
August 2016

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

J Clin Oncol 2016 08 18;34(24):2866-73. Epub 2016 Jul 18.

Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.5936
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.5936DOI Listing
August 2016

Resisting Resistance: Targeted Therapies in Lung Cancer.

Trends Cancer 2016 07;2(7):350-364

Department of Thoracic Oncology, Massachusetts General Hospital Cancer Center, 32 Fruit Street, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trecan.2016.05.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091655PMC
July 2016

Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?

Oncologist 2016 06 31;21(6):662-3. Epub 2016 May 31.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2016-0179DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912373PMC
June 2016

Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle.

Clin Cancer Res 2016 06;22(11):2613-7

U.S. Food and Drug Administration, Silver Spring, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2643DOI Listing
June 2016

Crizotinib Resensitization by Compound Mutation.

N Engl J Med 2016 05;374(18):1790-1

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1601366DOI Listing
May 2016